Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well pazopanib hydrochloride works in
treating patients with stage IV or recurrent nasopharyngeal cancer. Pazopanib hydrochloride
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and
by blocking blood flow to the tumor.